# Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

> **NCT03172455** · — · NO_LONGER_AVAILABLE · sponsor: **Impatients N.V. trading as myTomorrows**

## Conditions studied

- Acute-graft-versus-host Disease
- Steroid Refractory Acute Graft Versus Host Disease
- Graft-versus-host-disease
- Graft Vs Host Disease
- Alpha 1-Antitrypsin Deficiency
- Alpha-1 Proteinase Inhibitor
- Alpha-1 Protease Inhibitor Deficiency
- Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant

## Interventions

- **DRUG:** Glassia

## Key facts

- **NCT ID:** NCT03172455
- **Lead sponsor:** Impatients N.V. trading as myTomorrows
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03172455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03172455, "Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03172455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*